The MARIPOSA and MARIPOSA-2 phase III trials of amivantamab and lazertinib (third generation EGFR TKI) as first-line therapy for EGFR+ NSCLC are ongoing. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.